Pioglitazone (Actos) is a selective peroxisome proliferator-activated receptor gamma stimulator. Pioglitazone (Actos) selectively stimulates the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) and to a lesser extent PPAR-α. Pioglitazone (Actos) modulates the transcription of the insulin-sensitive genes involved in the control of glucose and lipid metabolism in the muscle, adipose tissue, and the liver. As a result, pioglitazone (Actos) reduces insulin resistance in the liver and peripheral tissues. Pioglitazone (Actos) increases the expense of insulin-dependent glucose. Pioglitazone (Actos) decreases withdrawal of glucose from the liver. Pioglitazone (Actos) reduces quantity of glucose, insulin and glycated hemoglobin in the bloodstream.
J Cell Mol Med. 2020 Jun;24(12):6833-6845.
Seizure-induced impairment in neuronal ketogenesis: Role of zinc-α2-glycoprotein in mitochondria
Pioglitazone purchased from AbMole
|Source||J Cell Mol Med (2020 Jun). Figure 2. Pioglitazone (Abmole Bioscience, Houston, TX, USA)|
|Incubation Time||24 hours|
|Results||Compared to the DMSO group, a 24-hour treatment with pioglitazone increased the levels of the ZAG protein (1.013 ± 0.135 vs 0.654 ± 0.090, P = 0.004, n = 4) and AZGP1 mRNA (1.474 ± 0.078 vs 1, P = 0.003, n = 3) (Figure 2B,C), while GW9662 significantly decreased the levels of the ZAG protein (0.361 ± 0.097 vs 0.654 ± 0.090, P = 0.013, n = 4) and AZGP1 mRNA (0.482 ± 0.153 vs 1, P = 0.002, n = 3) (Figure 2B,C).|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 10 mg/mL|
|Related PPAR Products|
Lanifibranor (IVA-337) is a peroxisome proliferator-activated receptors (PPAR) agonist, with EC50s of 1.5, 0.87 and 0.21 μM for human PPARα, PPARσ and PPARγ, respectively.
Balaglitazone is an agonist of peroxisome proliferator-activated receptor (PPAR) γ, with an EC50 of 1.351 μM for human PPARγ.
Elafibranor (also known as GFT-505) is a dual PPARα/δ agonist with EC50s of 45 and 175 nM, respectively.
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity, with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
Rosiglitazone HCl is a blood glucose-lowering drugs, stimulating insulin secretion by binding to the PPAR receptors in fat cells.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.